PR-15 is under clinical development by advanceCor and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PR-15’s likelihood of approval (LoA) and phase transition for Carotid Artery Stenosis took place on 01 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 01 Feb 2021 increased PR-15’s LoA and PTSR for Stroke.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PR-15 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PR-15 (revacept, GPVI-Fc) is under development for the treatment of symptomatic carotid stenosis, acute coronary syndrome, transient-ischemic attacks, Amaurosis fugax or stroke. It is administered through intravenous route. The drug candidate targets platelet glycoprotein VI. It is a fusion protein consisting of the Fc part of human IgG1 GPVI (glycoprotein VI). The drug candidate was also under development for the treatment of atherosclerosis.
advanceCor that engaged in developing innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. The company is headquartered in Martinsried, Planegg, Germany.
Quick View PR-15 LOA Data
|Highest Development Stage|